Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices.
Perspectives in the Treatment of Heart Failure with Preserved Ejection Fraction: From Drugs to Devices. Curr Top Med Chem. 2020;20(4):266-271 Authors: Banovic M, Bojanic M, Nikolic SD PMID: 32238128 [PubMed - as supplied by publisher]
Sometimes when the discussion of tackling the novel coronavirus comes up, the use of medical devices gets lost in the shuffle. Most of the conversation surrounding COVID-19 comes from either the promise of a vaccine or the expansion of tests. Abiomed is adding to the conversation surrounding medtechâs potential contribution to the treatment of COVID-19 patients. Monday, the Danvers, MA-based company by receiving Emergency Use Authorization for a device to treat COVID-19 related right heart failure patients. The Impella RP is a temporary heart pump that provides circulatory support for patients who develop...
Resumo A doen ça de coronavírus 2019 (COVID-19) é uma pandemia global afetando o mundo, estando presente em mais de 1.300.000 pacientes. O COVID-19 age pelo receptor da enzima conversora de angiotensina 2 (ECA2). As comorbidades cardiovasculares são mais frequentes com COVID-19, e cerca 10% de casos desenvolv em miocardite (22% de pacientes críticas). Mais pesquisas serão necessárias para continuar ou descontinuar inibidores de ECA e bloqueadores dos receptores da angiotensina, que são essenciais para hipertensão e insuficiência cardíaca em COVID-1...
The authorization allows use of the temporary heart pump in the treatment of right heart failure or decompensation, including pulmonary embolism, caused by COVID-19 complications.FDA Approvals
Publication date: Available online 31 May 2020Source: Revista Clínica Española (English Edition)Author(s): A. González-Franco, L. Manzano
by Stephen P. Wood, MS, ACNP-BC I stood facing the iPad attached to a rolling stand punching in the phone number of the young granddaughter of my intensive care unit patient. He arrived less than twenty-four hours before. I had taken the call the day before from the outside hospital emergency department and the story was grim. This was a seventy-six-year-old male who had acute myeloid leukemia, hypertension, as well as a history of congestive heart failure. He had been sick for the past two days with a fever, a cough and weakness.…
This article will explain the pathophysiology and benefits of exercise in those with the condition, as well as provide recommendations for home-based training for individuals with CHF.
To evaluate associations of high-sensitivity cardiac troponin-T (cTnT) with cardiovascular disease (CVD), heart failure (HF), and mortality in community-dwelling women and men.
Cardiovascular comorbidities and risk reduction play a major new role in pharmacologic therapy for type 2 diabetes, with sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists now recommended as part of the glucose-lowering regimen for patients who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high-risk, chronic kidney disease (CKD) or heart failure (HF).
Publication date: August 2020Source: IJC Heart &Vasculature, Volume 29Author(s): Inder Anand, Jeffrey L. Ardell, Doug Gregory, Imad Libbus, Lorenzo DiCarlo, Rajendra K. Premchand, Kamal Sharma, Sanjay Mittal, Rufino Monteiro
Authors: Tzikas S, Papadopoulos C, Evangeliou AP, Vassilikos V PMID: 32470561 [PubMed - as supplied by publisher]